Journal article
Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group
Abstract
Objectives: To determine thetolerability and efficacy of daily oralmarimastat (BB-2516 in patients withmetastatic melanoma and to determine thematrix metalloproteinase (MMP) activity,tumour necrosis, peri- and intra-tumoralfibrosis and tumor inflammation in pre- and post-treatmenttumor biopsies.Patients and methods: Patients withmeasurable metastatic melanoma who hadreceived no more than one priorchemotherapy regimen and lesions accessiblefor …
Authors
Quirt I; Bodurtha A; Lohmann R; Rusthoven J; Belanger K; Young V; Wainman N; Steward W; Eisenhauer E
Journal
Investigational New Drugs, Vol. 20, No. 4, pp. 431–437
Publisher
Springer Nature
Publication Date
November 2002
DOI
10.1023/a:1020625423524
ISSN
0167-6997